1. Generics Bulletin

Towa Completes Deal For Pensa

Transaction Worth €329m Was Agreed In Late 2019

 
• By Dave Wallace

Japan’s Towa has completed its €329m deal for the Pensa Investments generics business of Spain’s Esteve.

Handshake_Spain_Japan
Japan’s Towa has completed the deal with Spain’s Esteve • Source: Shutterstock

Japan’s Towa Pharmaceutical has completed its €329m ($364m) deal to acquire the [Pensa Investments] generics business from Spain’s Esteve.

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.